Summit Therapeutics Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Summit Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2019 to Q2 2024.
  • Summit Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$60.4M, a 310% decline year-over-year.
  • Summit Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$162M, a 72.9% increase year-over-year.
  • Summit Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$615M, a 681% decline from 2022.
  • Summit Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$78.8M, a 11.1% increase from 2021.
  • Summit Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$88.6M, a 68.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$162M -$60.4M -$45.7M -310% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$116M -$43.5M +$499M +92% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 -$615M -$36.6M -$17.3M -90.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 -$598M -$21.3M +$117K +0.55% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 -$598M -$14.7M +$2.05M +12.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$600M -$542M -$521M -2435% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 -$78.8M -$19.2M +$7.87M +29% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 -$86.7M -$21.4M -$1.79M -9.11% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$84.9M -$16.8M +$7.65M +31.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 -$92.5M -$21.4M -$3.91M -22.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$88.6M -$27.1M -$13.6M -100% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$75M -$19.6M -$1.86M -10.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$73.2M -$24.4M -$9.14M -59.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$64.1M -$17.5M -$11.4M -185% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 -$52.7M -$13.5M Oct 1, 2020 Dec 31, 2020 10-K/A 2022-12-21
Q3 2020 -$17.7M -$11.4M -178% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$15.3M -$8.6M -129% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$6.13M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q3 2019 -$6.38M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$6.68M Apr 1, 2019 Jun 30, 2019 8-K 2020-09-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.